Amylin-Based Weight Loss Drugs Explained: Cagrilintide, Petrelintide, and Amycretin

Amylin is emerging as the next major target in weight-loss medicine, offering a different mechanism than GLP-1 with a key advantage: gentler side effects. Three drugs lead this category, cagrilintide, petrelintide, and amycretin, and while all harness amylin, they do so in different ways. All three are investigational. Understanding amylin helps explain why these drugs matter and how they might complement or compete with the GLP-1 drugs everyone knows. Here’s the breakdown.

What Amylin Does

Amylin is a hormone your pancreas releases alongside insulin when you eat. It promotes fullness through several routes: it slows how fast your stomach empties, signals satiety directly to the brain, and helps restore your body’s sensitivity to leptin (another fullness hormone). This is a genuinely different pathway from GLP-1, which is why amylin drugs can be combined with GLP-1 drugs for added effect, and why their side-effect profiles differ.

The appeal is tolerability. GLP-1 drugs are effective but often cause significant nausea and vomiting, which drives many people to quit. Amylin-based drugs have shown notably milder gastrointestinal side effects in trials, which could make them easier to stay on long-term.

The Three Compared

Here’s how the leading amylin-based drugs differ.

Cagrilintide: The Established One

Cagrilintide is a long-acting amylin analog and the most developed of the group, largely because it’s the amylin component of CagriSema (the cagrilintide-plus-semaglutide combination). On its own, a phase 2 trial published in The Lancet in 2021 found it produced about 10.8% weight loss over 26 weeks with good tolerability. It’s now being advanced both as a standalone drug and as part of the combination, making it the reference point for the whole category.

Petrelintide: The Tolerability Leader

Petrelintide is also a pure amylin analog, and its calling card is exceptional tolerability. In its phase 2 trial it produced up to about 10.7% weight loss, and remarkably, at the most effective dose there were reportedly no cases of vomiting and no discontinuations due to gastrointestinal side effects. For a drug delivering double-digit weight loss, that’s an unusually clean profile. Consider a hypothetical patient who couldn’t tolerate a GLP-1 drug because of relentless nausea: petrelintide is designed precisely for them.

Amycretin: The Hybrid

Amycretin is the outlier because it’s not a pure amylin drug. It’s a single molecule that activates both the amylin and GLP-1 receptors, combining two pathways in one. This gives it a higher ceiling: its injectable form reached the low 20% range in trials, higher than the pure amylin analogs. The trade-off is that combining GLP-1 activity brings back somewhat more of the GLP-1-style side effects, though still manageable.

Why This Category Matters

Amylin drugs represent a shift beyond the GLP-1-only era. They offer a complementary mechanism, better tolerability, and the potential to be combined with GLP-1 drugs for greater effect. Some experts see amylin as central to the next generation of obesity treatment. All three drugs here are investigational, so none is available yet, but the category is advancing quickly.

What This Means for You Right Now

None of these amylin-based drugs is available, and TrimRx does not offer them. TrimRx provides currently available options, including compounded semaglutide and compounded tirzepatide plus brand GLP-1 injectables. If weight loss is your goal now, those are the tools to consider while the amylin drugs work through development.

Frequently Asked Questions

How are amylin drugs different from Ozempic?

Amylin drugs work through the amylin hormone pathway, while Ozempic (semaglutide) works through GLP-1. Both promote fullness, but through different mechanisms, which is why amylin drugs tend to cause milder gastrointestinal side effects and can be combined with GLP-1 drugs for added effect.

Which amylin drug produces the most weight loss?

Amycretin has the highest ceiling because it combines amylin with GLP-1 activity (reaching the low 20% range in its injectable form). The pure amylin analogs, cagrilintide and petrelintide, produce around 10% to 11%, with petrelintide standing out for exceptionally mild side effects.

Are amylin weight-loss drugs available yet?

No. Cagrilintide, petrelintide, and amycretin are all investigational and not FDA approved. They’re advancing through clinical trials, but none is currently available, and TrimRx does not offer them.

To focus on treatments available today, you can explore the options available to you now with a licensed provider.

This information is for educational purposes and is not medical advice. These amylin-based drugs are investigational and not FDA approved; details and timelines may change. Consult a healthcare provider before starting any medication. Individual results may vary.